Daniel Lynch, Director at SpringWorks Therapeutics, Inc. (SWTX), sold 400 shares at $60.00 ($24K) on 2025-02-14, disclosed to the SEC on 2025-02-19.
Scheduled sale ($24k) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| BPMC | SELL | 2018-02-16 | $1.0M | — | Filing → |
| BPMC | SELL | 2018-02-14 | $2.6M | — | Filing → |
| BPMC | SELL | 2017-11-17 | $420K | — | Filing → |